Darizmetinib

N/A

Report date: 2026/04/21 20:00:18
NMEFirst In Class

Base Information

Drug NameDarizmetinib
Drug Alias NameHRX-0215HRX-215LN-3348
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDual specificity mitogen-activated protein kinase kinase 4 inhibitors
TargetsDual specificity mitogen-activated protein kinase kinase 4
Therapy Area/IndicationsLiver Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesHepaRegeniX GmbH
China Registration ClassN/A

Develop Information

Active CompaniesHepaRegeniX GmbH
Inactive CompaniesN/A
Active IndicationsLiver Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A